Session 12 – Asian Opportunities & Collaborations
Date: 24 July (Friday) 12:20 – 13:50 (GMT+8)
Venue: 701EF, 7F, TaiNEX2 / Online event platform
Dr Murali is the immediate past president of ABLE. As President of ABLE, Dr Murali catalyzed the growth of India’s biotechnology sector and the sector is a now $50 billion BioEconomy. He was instrumental in ushering many regulatory changes brought about by the federal government, pushed governments in the state to set up incubators for startups, formulate state-level biotech policies to boost the industry. Dr Murali is also a Serial Entrepreneur. In the past 30+ years he has developed several first of its kind natural products and built 8 companies. One taken to public in Europe. Dr Murali has also had a 4-year stint as the President & CEO in US silicon valley company. He has several patents and publications to his credit.
Currently, he is the founder of a startup company, Jananom, based in Coimbatore, Tamil Nadu and Bangalore, Karnataka. Jananom focusses on the confluence of food, drugs and the gut microbiome.
Dr Murali has over 30 years of experience in Pharmaceutical & Healthcare R&D, holds a Ph.D in Microbiology, D.Sc. in Plant Biotechnology.
Speech title & Synopsis
The talk would address several changing dynamics across Indo-Taiwan bio-pharma business corridor in the present and immediate future scenarios, post COVID-19.
Some of the key areas where increase interaction and bi-lateral relationship could benefit companies in both countries include:
1. Sourcing APIs
2. Medical devices manufacturing and components
3. Drug repositioning & repurposing